Richard William Scalzo
CIK 1789545 · Chief Financial Officer · last filed 2025-12-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.23M
Companies
2
Total Filings
36
Lifetime Open-Market Net
-$8.71M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Chief Financial Officer | 19,422 | $15.70 | $304.9K | $0 | 1 | 2025-12-17 |
| DYN | SVP, Head of Finance & Admin. | 122,330 | $18.19 | $2.23M | -$8.71M | 35 | 2025-03-13 |
Recent Filings · Page 4 of 4
36 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-07-06 | DYN | Grant (A) | — | $0 | EDGAR |
| 2022-06-15 | DYN | Disp (D) | −333 | -$1.6K | EDGAR |
| 2022-03-14 | DYN | Sell (S) | −308 | -$2.7K | EDGAR |
| 2021-12-14 | DYN | Grant (A) | +16,696 | $0 | EDGAR |
| 2021-09-22 | DYN | Sell (S) | −859 | -$13.7K | EDGAR |
| 2020-09-18 | DYN | Grant (A) | +11,465 | $0 | EDGAR |
Showing 31–36 of 36
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.